Site search

Clear filter
2923 results for '' found
Navitor Post-Market Clinical Follow Up Study [VISTA Study] (NCT06008080)
/
An Open-label Extension Study Evaluating the Long-term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects with Myotonic Dystrophy Type I (NCT069266
An Open-label Extension Study Evaluating the Long-term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects with Myotonic Dystrophy Type I (NCT069266
/
A Phase 1/2, Randomized, Double-blind, Placebo controlled Single- and Multiple dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX 670 in Adult
/
A Phase 1/2, Randomized, Double-blind, Placebo controlled Single- and Multiple dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX 670 in Adult
A Phase 1/2, Randomized, Double-blind, Placebo controlled Single- and Multiple dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX 670 in Adult
/
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants with Moderately to Severely Active Crohn’s
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants with Moderately to Severely Active Crohn’s
/
A Phase 2 Platform Study of Novel Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma VELOCITY-HNSCC Substudy-01: A Phase 2 Study of Novel Combination Therapies in Pa
A Phase 2 Platform Study of Novel Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma VELOCITY-HNSCC Substudy-01: A Phase 2 Study of Novel Combination Therapies in Pa
/
An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD) (NCT05518149)
/
An Interventional Study to Evaluate Treating to a Target of Transmural Healing in Patients with Moderately to Severely Active Crohn’s Disease [VECTORS] (NCT06257706)
An Interventional Study to Evaluate Treating to a Target of Transmural Healing in Patients with Moderately to Severely Active Crohn’s Disease [VECTORS] (NCT06257706)
/
VANTAGE Clinical Trial: (Evaluation of TAVI using the NAVITOR valve in a Global Investigation) (NCT04788888)
VANTAGE Clinical Trial: (Evaluation of TAVI using the NAVITOR valve in a Global Investigation) (NCT04788888)
/
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Partici
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Partici
/
25 26 27 28 29